6 news items
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
BMY
23 May 24
GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
BMY
10 May 24
hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY
26 Apr 24
(GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid-requiring febrile syndrome
FDA Approves Vertex Pharmaceuticals (NASDAQ:VRTX) VX-407 for Phase I Study in Groundbreaking Move Against Polycystic Kidney Disease"
ATNM
AZN
BMY
25 Mar 24
that VX-548 significantly reduced pain intensity across various conditions and settings. Vertex is poised to submit a new drug application for VX-548
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy
BMY
JNJ
LEGN
20 Mar 24
remains the most capital-intensive for GenScript due to heavy R&D spending.
Of GenScript’s $430 million in R&D spending last
d6pqm
BMY
7 Mar 24
), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid-requiring febrile syndrome (without
- Prev
- 1
- Next